Until the approval of selpercatinib (a first-in-class, highly selective, and potent RET inhibitor with central nervous system penetration) in May 2020, the treatment options for patients with RET-activated cancers were limited to standard therapies such as multikinase inhibitors (MKIs) or platinum chemotherapy +/− immune checkpoint inhibitors (ICIs) [6]. The gene discussed is RET; the disease is cancer.